Navigation Links
EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
Date:2/18/2008

Out-Licensing Enhances EUSA's Strategic Focus on Late-Stage and Marketed

Products

DOYLESTOWN, Pennsylvania and OXFORD, England, February 18 /PRNewswire/ -- EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has out-licensed the exclusive world-wide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK) for a consideration of up to $44 million, comprising an upfront fee and development milestones, plus royalties on future sales. As part of the agreement EUSA will pay approximately 50% of the overall consideration to its development partner for the antibody, Vaccinex Inc. GSK will fund and conduct all future development, production and commercialization of the product.

Interleukin-6 is a pro-inflammatory cytokine and B-cell growth factor and acts as a resistance factor to standard chemotherapy. EUSA's product, OP-R003, is the first fully human anti-interleukin-6 antibody, with target indications in oncology and inflammatory diseases. OP-R003 is derived from a first generation murine antibody, elsilimomab, which has achieved promising clinical results as a lymphoma therapy. As a fully human antibody, OP-R003 has the potential to offer improved tolerability and a superior safety profile.

EUSA acquired OP-R003 as part of the company's 2007 acquisition of OPi SA. OPi had previously entered a collaboration with Vaccinex, a specialist antibody discovery and development company, to optimize and develop OP-R003 as a therapy for rheumatoid arthritis and lymphoma.

"The out-licensing of this early-stage antibody is another strategic milestone for EUSA, as we continue to focus our business on marketed and late-stage products in the oncology, pain control and critical care areas," said Bryan Morton, Chief Executive of EUSA Pharma.

Commenting on the acquisition, Brian McVe
'/>"/>

SOURCE EUSA Pharma Inc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)...cognise service excellence during National Custome... London (PRWeb UK) July 3, 2009 -- Companie...ged to celebrate the importance of excellent custo...rvice Week - 5-11 October., , ,Employers in all se...p and local authority see the week, which is organ...
(Date:7/3/2009)...th in middle age may triple the risk, study shows ... Middle-aged adults who live alone are twice as li...ter in life compared to those who are married or l...gher among those who are divorced or widowed, acco...chers. , The study included 2,000 men and women...
(Date:7/3/2009)...ia/ -- Sundia MediTech, a leading,integrated phar... in Shanghai,China announced today that Dr. Chen... Chemistry Services. , Prior to joining Sun...drug,discovery and development company in San Die...enior Director of Medicinal Chemistry of Neurocrin...
(Date:7/3/2009)...om launches new content to include information abo...o best deal with these health issues. , ...-- ReverseAges.com has recently launched a new ser...ommon health issues such as high blood pressure. H...rs, and the new content on ReverseAges.com address...
Breaking Medicine News(10 mins):Health News:Businesses Urged to Sign Up and Celebrate Customer Service 2Health News:Living Alone Increases Odds of Developing Dementia 2Health News:Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry 2
...must in the medicine chest of a pregnant woman. It... lead to serious birth defects// in the baby. Foli...stroke and heart disease. Now, there appears to be... has shown. Folic acid may actually reduce low fr...
...n Ltd has received tentative approval from the US ... drug Sertraline Hydrochloride for// treatment of ...rtraline Hydrochloride tablets will be the AB-rate...zer's Zoloft tablets of 25mg, 50mg and 100mg dosag...
...mination in fish and birds in the northeastern Uni...five "hotspots" where concentrations// of the elem... health. The US and Canadian research team focuse...yellow perch and common loons, but it also took in...
...ormance measures for heart failure do not appear t... according to a study.// Heart failure continues ...d States: the overall prevalence of heart failure ...h 550,000 new cases being reported each year. Hear...
Other Medicine News:Health News:Mercury Contamination (Hotspots) Identified 2Health News:Most Hospital Performance Measures for Heart Failure Not Linked to Improved Patient Outcomes 2Health News:Most Hospital Performance Measures for Heart Failure Not Linked to Improved Patient Outcomes 3
(Date:6/28/2009)...CORONADO, Portugal, June 29 Data p...d-on treatment with the novel,once-daily anti-ep... resulted,in a marked and sustained decrease in s...esults from the one-year extension of a pivotal Es...ted at the International Congress for Epilepsy in,...
(Date:6/26/2009)..., June 26 Sanofi-avent...made aware of data associated with a retrospective... of these data clearly show that no definitive con...relationship between Lantus(R) (insulin glargine [...ncies, as the authors of the study point out. , ...
(Date:6/26/2009)...Recommends Approval of New Anti-TNF Therapy in Thr...oinjector , , HORSHAM, Pa. and KENILWORTH, N.J.... Biotech Inc. and Schering-Plough Corporation (NYS...Medicinal Products for Human Use (CHMP) of the Eur...pinion recommending the approval of SIMPONI(TM) (g...
(Date:6/25/2009)...June 25 "Congratulations President... companies to cut prescription costs for the elder...ompany, Inc. "We thought you should know that you ...e same for psoriasis sufferers of all ages." , ,...Inc., and the submission of their findings from a ...
Breaking Medicine Technology:Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 2Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 4Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 5Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 6Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 7Sanofi-aventis Stands Behind the Safety of Lantus(R) 2Sanofi-aventis Stands Behind the Safety of Lantus(R) 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10Innovative Psoriasis Treatment PSORENT(R) Announces Healthcare Cost Savings Potential Consistent with President Obama's Announcement on Healthcare Reform 2Anti VEGF drugs for retinal diseases could have serious side effects scientists caution 28569 1Anti VEGF drugs for retinal diseases could have serious side effects scientists caution 28569 2Anti VEGF drugs for retinal diseases could have serious side effects scientists caution 28569 3Vineland Welcomes Dr Isabelle Lesschaeve as Research Chair Sensory and Consumer Sciences 8831 1Vineland Welcomes Dr Isabelle Lesschaeve as Research Chair Sensory and Consumer Sciences 8831 2Younger People Not Seniors Getting More Colds and Feeling Run Down 28566 1Younger People Not Seniors Getting More Colds and Feeling Run Down 28566 2RainDance Technologies to Present Sequence Enrichment Using Droplet Based Microfluidics Workshop at ASHG 2008 8830 1RainDance Technologies to Present Sequence Enrichment Using Droplet Based Microfluidics Workshop at ASHG 2008 8830 2
...eriority in Primary Endpoint of,In-Segment Late Lo... Target Vessel Failure and Superiority in Major Ad... Trial -, ABBOTT PARK, Ill., March 24, 2007 /PRNew...tt,s SPIRIT III U.S. pivotal clinical,trial at the... New,Orleans demonstrated the following key result...
...7 /PRNewswire/ -- A large patient,registry of "rea...Coronary Stent reported favorable safety and effic...linical investigators at the of,Cardiology,s 56th ...egistry is a prospective, single-arm study designe...y intervention (PCI,or balloon angioplasty) with t...
Other Medicine Technology:Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 2Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 3Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 4Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 5Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 2Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 3Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 4
The SOLX DeepLight Glaucoma Treatment System will provide less invasive, yet highly effective glaucoma treatments through the use of our DeepLight Gold Micro-Shunt (GMS) and DeepLight 790 Titanium Sa
The Verity ADx pacemaker family, which includes the world's longest lasting single- and dual-chamber pacemakers, provides clinicians with a variety of feature options and header configurations to mee
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices.
The Identity ADx pacemaker family, which includes the world's smallest dual-chamber pacemaker, provides clinicians with the most advanced pacemaker technology available, including the revolutionary A
Medicine Products: